About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNPhase 2NCT05675033

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

In order to further evaluate the efficacy of immunotherapy combined with antivascular therapy in the real world, we used Serpluimab combined with Bevacizumab and platinum-based chemotherapy in previou...

Lead sponsor: Fujian Cancer Hospital•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Mei Fang Li, MD

CONTACT

+8615985795022 362952772@qq.com

Sponsors

Lead Sponsor

Fujian Cancer Hospital

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Fully understood this study and voluntarily signed the informed consent form (ICF);
•-≥ 18 years and ≤ 75 years old;
•ECOG score 0-1;
•Non-squamous NSCLC;
•stage IV;
•EGFR and ALK negative;
•Treatment-naive;
•According to RECIST1.1 criteria, there are measurable or evaluable lesions.

Exclusion Criteria

•Tumor histology or cytology confirmed that it was associated with squamous cell carcinoma or small cell lung cancer;
•Patients with severe organ dysfunction were indicated by examination, Exclude subjects with any active, known or suspected autoimmune diseases;
•The estimated survival time is less than 3 months.

Related studies

RECRUITINGPhase 2

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

NCT05528458 · Lung Adenocarcinoma

Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma

NCT07479095 · Lepidic-Predominant Lung Adenocarcinoma, Lung Adenocarcinoma

RECRUITINGPhase 2

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

NCT05198830 · Lung Adenocarcinoma, Lung Large Cell Carcinoma, and more

Engagement of Veterans With Lung Cancer

NCT07219251 · Lung Cancer (NSCLC), Lung Adenocarcinoma, and more

RECRUITINGEARLY Phase 1

Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

NCT07235280 · Lung Adenocarcinoma, Stage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 9, 2023Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE2

Enrollment50

Start dateJan 2023

Last updatedJan 9, 2023

Condition

Lung Adenocarcinoma Stage IV Non-small Cell Lung Cancer PD-1 Inhibitor VEGF

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 9, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions